Delivering better treatments
Camurus is Swedish research-based pharmaceutical company established 2004, committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders.

New drug products are based on the proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. Camurus has approximately 85 employees with the head office located in Lund. The corporate culture is driven by innovation, strong collaboration internally and externally, ownership by everyone, quality, and passion about realizing our ideas and goals.

The cornerstones of the operations are innovation and efficient development of therapeutics with the potential to significantly improve the treatment and quality of life of patients with severe and chronic diseases. Progress is accomplished thanks to skilled, professional and dedicated teams and unique technologies.

Development create value across the pharmaceutical development cycle, from early programs to partnerships with international pharmaceutical companies. To maximize the value creation for the products, Camurus is building their own European commercial organization with an initial focus on the opioid dependence market and other specialty markets with suitable dynamics and a concentrated prescriber base.

For more information see The CEO statement, appendix 1 or visit http://www.camurus.com.

Technologies

FluidCrystal® - smart and versatile drug delivery
Camurus FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines.
For more information about the FluidCrystal® technology, see appendix 2.

Buvidal® (CAM2038) Opioid dependence
Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence
- Buvidal® is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents

Lund, Sweden – 22 November 2018 – Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged released buprenorphine) for the treatment of opioid dependence in adults and adolescents from 16 years of age. This marks the first approval of a long-acting treatment for opioid dependence in the EU. For more information, please see the full Press release in appendix 4.

Transforming Opioid dependence treatment
Opioid dependence is a serious, chronic, relapsing disease. It is a growing global health problem and the largest burden to society of all drugs. Medication assisted treatment (MAT) with daily buprenorphine and methadone is considered standard of care and effective but is also associated with limitations such as poor treatment adherence, misuse and diversion.
Buvidal includes two long-acting subcutaneous buprenorphine investigational products for treatment of opioid dependence. The product candidates are based on Camurus’ proprietary FluidCrystal® injection depot technology and are intended for either weekly (q1w) or monthly (q4w) administration, each in multiple doses to allow individualized treatment of patients with opioid dependence. Buvidal has the potential to free patients from the burden and stigma associated with the daily, often supervised, distribution and administration of medication.
The investigational products will be provided in prefilled syringes with thin needles, designed for convenient administration by healthcare personnel to ensure proper delivery and treatment compliance, and to minimize the risks of diversion, abuse, misuse, and accidental pediatric exposure. By reduced dosing frequency and thereby costs of treatment under supervision, as well as by improved treatment compliance, Buvidal also has the potential to generate substantial savings for healthcare and society.

Buvidal – Key target attributes
• Improved treatment adherence
• Reduced frequency of administrations – from 365 times to 12 or 52 times per year
• Minimized risk of diversion and misuse
• Eliminates risk of accidental pediatric exposure
• Flexible dosing and adjustable duration allow individualized therapy in all treatment phases
• Blocks the effects of illicit opioids
Delivery on strategy

 

Key Account Manager Stockholm/mellersta Sverige

This is a unique opportunity to launch Buvidal®, a new treatment alternative for opioid dependence, representing Camurus, an innovative Swedish research-based pharmaceutical company.

The position Key Account Manager Stockholm/mid Sweden

Reporting to the Country Lead Sweden & Denmark, the Key Account Manager will be responsible for the sales- and commercial activities, including market access, with a focus on Stockholm and mid Sweden. This includes regional analysis and planning, and the roll out of regional launch activities.

The successful candidate will be responsible for the launch of the first Camurus pharmaceutical product, Buvidal®, (prolonged release buprenorphine) for the treatment of opioid dependence in adults and adolescents from 16 years of age. Over time there will be other products from the clinical development pipeline.


The Key Account Managers key accountability is for sales in their region through development and execution of sales strategy and leading the effectiveness and implementation of a regional plan. As Key Account Manager youwill work in a close partnership with a cross-functional Swedish team currently consisting of a Key Account Manager (southern Sweden), Country Lead Sweden & Denmark and a Medical Science Lead (MSL).

The Key Account Manager position is home based with frequent travelling in the region, along with frequent meetings with the Swedish team. The role requires fluency in Swedish and English. The position requires a valid driver’s license.

Role opportunities
• Launch Buvidal®, the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents
• Be part of Camurus, a research-based and innovative Swedish pharmaceutical company with a global presence.
• As Key Account Manager, be a regional leader with a broad responsibility for the sales- and commercial strategies and activities in the region
• Collaboratecross-functionally together with a professional team
• Be part of an exciting journey in a fast growing company, with great opportunities for personal development.

Required experience, skills and profile

We are looking for a candidate with a high drive and a strong engagement,a committed ambassador for Buvidal® and Camurus in the market.

The successful Key Account Manager candidate will be experienced in successful sales- and customer operations in the biotechnology or specialty pharmaceutical industry. Some market access experience is an advantage. She/he will previously have held a similar role or other relevant sales- or customer facing roles, and will have an ability and desire to work across the broad span of hands-on work, as well as contribute to the regional strategy and planning.

The person will be self-motivated and work consistently to deliver operational excellence in all activities.

The successful candidate for the position will be a recognized sales professional with a proven track-record of effective cross-functional collaboration. It is important that the individual appointed identifies with the strong innovative and entrepreneurial spirit that is the trademark of Camurus.


Education qualifications:
• Degree level, ideally science/medicine/pharmacy or business

Certifications:
• Qualifying educational degree or completed relevant local certification to work with pharmaceutical product in market (LIF)
• Valid driver’s license

Learning Experience / Work Experience
• Solid experience and track record from a commercial role within pharmaceuticals, including sales
• Ideally involved in a product launch for a local sales territory/region
• Experienced in developing, managing and maintaining relationships with key prescribers and other healthcare professionals (HCPs)
• Experience from market access and management of different regional stakeholders is an advantage
• Understanding of the current local code of conduct
• Experience in the CNS area or with other highly specialised therapeutic area is an advantage
• Experience with working in a company at the start-up phase of commercial operations.

Languages
• Fluency in spoken and written Swedish and English.

Systems
• Experienced user in MS Office package

Personal Attributes
• Entrepreneurial spirit and good judgment in managing the business.
• High level of self-leadership and strong negotiation skills.
• Solution-oriented mindset
• Capability to work independently and being a team player at the same time.
• Prepared for significant travel and customer interaction.

Location
• In the region, preferably in the Stockholm area

Contact
For further information about the Key Account Manager position please contact Magnus Klingberg, Recruitment consultants at PeakSearch. Apply for the position at http://www.peaksearch.se.
Magnus Klingberg, Recruitment Consultant, +46-70-6780992, +46-8-54500100
magnus.klingberg@peaksearch.se